Cumberland Biotherapeutics, LLC

Cumberland Biotherapeutics is a privately held biopharmaceutical company headquartered in Sewanee, Tennessee, founded in 2020. The company develops and commercializes bioceutical and phytotherapeutic products that combine modern clinical research with botanical science to address unmet medical needs. The company's commercial product portfolio includes DentoClude™ F, an FDA-registered in-office dental desensitizing device formulated with submicron bioactive glass, fluoride, and botanical extracts designed to block dentin tubules and relieve tooth sensitivity; and LigoFlex ES, a joint and inflammation support product formulated as a plant-based COX-2 inhibitor for rheumatoid arthritis, osteoarthritis, and mobility support. Cumberland Biotherapeutics integrates Ayurvedic medicine principles with rigorous scientific validation across research-driven formulation, botanical expertise, and patient-centered development. The company's pipeline includes additional bioceutical therapies in oral health, joint health, systemic and localized inflammation, and wellness/preventive health applications. The company markets products to dental professionals, healthcare providers, and potential distribution and research partners.